XASE · Healthcare · Biotechnology
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.19 | -0.18 | +5.26% | $1.6M | ✅ Beat | +4.54% | -12.33% | — |
| 2026-03-19 | Q4 2025 | -0.21 | -0.17 | +19.05% | $968,127 | ✅ Beat | +2.00% | -2.23% | +0.84% |
| 2025-11-10 |
| Q3 2025 |
| -0.20 |
| -0.24 |
| -20.00% |
| $811,414 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.19 | -0.22 | -15.79% | $894,086 | ❌ Miss | +1.23% | -5.22% | -2.81% |
| 2025-03-20 | Q4 2024 | — | -0.23 | — | $761,165 | — | +1.76% | -6.11% | -20.93% |
| 2024-08-09 | Q2 2024 | — | -0.42 | — | $611,500 | — | +1.93% | +2.25% | +0.96% |
| 2024-05-22 | Q1 2024 | — | -0.32 | — | $646,635 | — | +4.12% | +12.71% | -11.34% |
| 2024-04-16 | Q4 2023 | — | -0.85 | — | $531,459 | — | -0.86% | -9.81% | -1.18% |
Showing last 8 quarters.